Patent application number | Description | Published |
20080206958 | ENHANCEMENT OF ELECTRON AND HOLE MOBILITIES IN <110> Si UNDER BIAXIAL COMPRESSIVE STRAIN - The present invention provides a semiconductor material that has enhanced electron and hole mobilities that comprises a Si-containing layer having a <110> crystal orientation and a biaxial compressive strain. The term “biaxial compressive stress” is used herein to describe the net stress caused by longitudinal compressive stress and lateral stress that is induced upon the Si-containing layer during the manufacturing of the semiconductor material. Other aspect of the present invention relates to a method of forming the semiconductor material of the present invention. The method of the present invention includes the steps of providing a silicon-containing <110> layer; and creating a biaxial strain in the silicon-containing <110> layer. | 08-28-2008 |
20080290409 | HALO-FIRST ULTRA-THIN SOI FET FOR SUPERIOR SHORT CHANNEL CONTROL - Superior control of short-channel effects for an ultra-thin semiconductor-on-insulator field effect transistor (UTSOI-FET) is obtained by performing a halo implantation immediately after a gate reoxidation step. An offset is then formed and thereafter an extension implantation process is performed. This sequence of processing steps ensures that the halo implant is laterally separated from the extension implant by the width of the offset spacer. This construction produces equivalent or far superior short channel performance compared to conventional UTSOI-FETs. Additionally, the above processing steps permit the use of lower halo doses as compared to conventional processes. | 11-27-2008 |
20090294854 | HALO-FIRST ULTRA-THIN SOI FET FOR SUPERIOR SHORT CHANNEL CONTROL - Superior control of short-channel effects for an ultra-thin semiconductor-on-insulator field effect transistor (UTSOI-FET) is obtained by performing a halo implantation immediately after a gate reoxidation step. An offset is then formed and thereafter an extension implantation process is performed. This sequence of processing steps ensures that the halo implant is laterally separated from the extension implant by the width of the offset spacer. This construction produces equivalent or far superior short channel performance compared to conventional UTSOI-FETs. Additionally, the above processing steps permit the use of lower halo doses as compared to conventional processes. | 12-03-2009 |
20090305471 | THIN SILICON SINGLE DIFFUSION FIELD EFFECT TRANSISTOR FOR ENHANCED DRIVE PERFORMANCE WITH STRESS FILM LINERS - The present invention provides a semiconducting device structure including a thin SOI region, wherein the SOI device is formed with an optional single thin diffusion, i.e., offset, spacer and a single diffusion implant. The device silicon thickness is thin enough to permit the diffusion implants to abut the buried insulator but thick enough to form a contacting silicide. Stress layer liner films are used both over nFET and pFET device regions to enhance performance. | 12-10-2009 |
Patent application number | Description | Published |
20090004293 | Phosphorous Containing Compounds Including Triphenylmethylphosphonate Esters for the Treatment of Melanoma and Other Cancers - Compounds and related methods for synthesis, and the use of compounds and combination therapies for the treatment of cancer and modulation of apoptosis in cells are disclosed. Particularly disclosed are phosphonate esters. Compounds, methods of making the compounds, medicaments and method of manufacture of medicaments and therapeutic methods with applications against cancer including breast cancer, melanoma, colon cancer, leukemia and lymphoma, and other cancer cells are described. | 01-01-2009 |
20090012088 | Compounds for the Treatment of Neurodegeneration and Stroke - Compounds and related methods for synthesis, and the use of compounds for the treatment of neurodegenerative diseases are disclosed. Compounds are disclosed in connection with PARG and/or PARP inhibition. Therapeutic applications are relevant for preventing or inhibiting neurological cell death for a variety of neurodegenerative conditions including Parkinson's disease, ischemia, and stroke. Also disclosed is a high-throughput screen for identifying compounds capable of inhibiting PARG and/or PARP. | 01-08-2009 |
20110257398 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation - Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3. In embodiments, compositions are capable of activation of procaspase-3. | 10-20-2011 |
20120040995 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS - Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds. | 02-16-2012 |
20130096133 | PROCASPASE-ACTIVATING COMPOUNDS AND COMPOSITIONS - The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells. | 04-18-2013 |
20130261124 | THERAPEUTIC METHODS AND AGENTS FOR TREATING MYOTONIC DYSTROPHY - The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids. | 10-03-2013 |
20140073609 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation - Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3. In embodiments, compositions are capable of activation of procaspase-3. | 03-13-2014 |
20140187500 | COMPOUNDS, CONJUGATES AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES - The present application provides, among other things, compounds, compositions and methods for treating various diseases including cancer. | 07-03-2014 |
20140288080 | THERAPEUTIC METHODS AND AGENTS FOR TREATING MYOTONIC DYSTROPHY - The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids. | 09-25-2014 |
20140343001 | INDOLE DERIVATIVES INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) - The present invention encompasses compounds having general formula (I) able to inhibit the lactate production (lactic acid) involved in the angiogenesis of tumoral tissues, in the glycolytic metabolic process of tumoral cells, of immune system cells in asthmatic diseases, in vascular cells in the pulmonary hypertension, in the treatment of chronic back pain or hyperoxaluria, and in the process by which the parasites protozoan causing malaria obtain most of the necessary energy. | 11-20-2014 |
20150017264 | PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY - The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds. | 01-15-2015 |
20150025083 | PROCASPASE COMBINATION THERAPY FOR GLIOBLASTOMA - The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds. | 01-22-2015 |
20150080405 | COMPOUNDS, COMPOSITIONS AND METHODS OF AGELASTATIN ALKALOIDS - The present invention, among other things, provides compounds, compositions and methods for treatment of cancer. In some embodiments, the present invention provides methods for treating blood cancer using agelastatin alkaloids. | 03-19-2015 |
Patent application number | Description | Published |
20100303878 | BIODEGRADABLE BIOACTIVE AGENT RELEASING MATRICES WITH PARTICULATES - The present invention is directed to biodegradable polymeric matrices for the controlled release of a hydrophilic bioactive agent. Generally, the biodegradable matrices include an aliphatic polyester copolymer and microparticulates that include the hydrophilic bioactive agent. In some embodiments, the matrix includes a second biodegradable polymer comprising hydrophilic and hydrophobic portions. Exemplary matrix forms are device coatings and medical implants. Matrices of the invention demonstrated high bioactive agent loading, were able to modulate release of the bioactive agent in a therapeutic manner, and also maintained high levels of activity for therapeutically useful large molecule bioactive agents, such as proteins. | 12-02-2010 |
20100303879 | SILANE-FUNCTIONALIZED HYDROPHOBIC a(1-4)GLUCOPYRANOSE POLYMERS AND POLYMERIC MATRICES FOR IMPLANTATION OR INJECTION - Silane-functionalized hydrophobic α(1→4)glucopyranose polymers and polymeric matrices are described. Biodegradable matrices can be formed from hydrophobic α(1→4)glucopyranose polymers with reactive pendent silyl ether groups. Reaction of the silyl ether groups provides improved matrix formation through bonding to a device surface of a device, polymer-polymer crosslinking, or both. Biodegradable matrices can be used for the preparation of implantable and injectable medical devices, including those that release a bioactive agent. | 12-02-2010 |
20110159101 | SILYL ETHER-MODIFIED HYDROPHILIC POLYMERS AND USES FOR MEDICAL ARTICLES - Silane-functionalized hydrophilic polymers and polymeric matrices are described. Hydrophilic matrices can be formed from the polymers, and can be used in association with the preparation of implantable and injectable medical devices. Exemplary devices include those having a durable lubricious coating formed from the hydrophilic polymers. | 06-30-2011 |
Patent application number | Description | Published |
20090280155 | Coating systems for the controlled delivery of hydrophilic bioactive agents - Described are coating systems for the controlled delivery of hydrophilic bioactive agents, for example, from implantable medical devices. The coating systems of the invention comprise (a) a polymeric basecoat layer containing one or more hydrophilic bioactive agents; and (b) an elution-controlling topcoat layer that comprises a poly(ethylene-co-vinyl acetate) copolymer. The elution rate of the hydrophilic bioactive agent can be controlled by varying the vinyl acetate concentration in the elution-controlling topcoat layer. | 11-12-2009 |
20100008966 | Medical Devices and Methods for Delivery of Nucleic Acids - Embodiments of the invention include devices for the release of nucleic acids and related methods. In an embodiment, the invention includes an active agent eluting coating including a polymeric matrix, a cationic carrier agent disposed with the matrix, and an active agent disposed within the matrix, the active agent including nucleic acids substantially uncomplexed with the cationic carrier agent. In an embodiment, the invention includes a method of making an implantable medical device including selecting a concentration of a cationic carrier agent corresponding to a desired elution profile, combining a matrix forming polymer, an active agent, a solvent, and the cationic carrier agent to form a coating composition having the selected concentration of the cationic carrier agent, the active agent comprising nucleic acids, and depositing the coating composition onto the surface of a substrate. Other embodiments are included herein. | 01-14-2010 |
20100158799 | METHOD AND COMPOSITION FOR BIOACTIVE AGENT RELEASE IN VIVO - A composition for bioactive agent release in vivo. The composition includes the bioactive agent in combination with a mixture of a first polymer component such as poly(butyl methacrylate) and a second polymer component such as poly(ethylene-co-vinyl acetate). | 06-24-2010 |
20110054417 | BIOACTIVE AGENT RELEASE COATING AND CONTROLLED HUMIDITY METHOD - A coating composition in the form of a one or multi-part system, and method of applying such a composition under conditions of controlled humidity, for use in coating device surfaces to control and/or improve their ability to release bioactive agents in aqueous systems. The coating composition is particularly adapted for use with medical devices that undergo significant flexion and/or expansion in the course of their delivery and/or use, such as stents and catheters. The composition includes the bioactive agent in combination with a first polymer component such as polyalkyl(meth)acrylate, polyaryl(meth)acrylate, polyaralkyl(meth)acrylate, or polyaryloxyalkyl(meth)acrylate and a second polymer component such as poly(ethylene-co-vinyl acetate). | 03-03-2011 |
20110144373 | WATER-SOLUBLE DEGRADABLE PHOTO-CROSSLINKER - Described herein is a degradable linking agent that includes a core molecule with one or more charged groups; and one or more photoreactive groups covalently attached to the core molecule by one or more degradable linkers. | 06-16-2011 |
20120021038 | COATING COMPOSITION - A wound spacer device comprising multiple beads connected by non-absorbable suture material is disclosed. The device can be applied, for example, by a first responder to an injured individual, or can be applied by a trauma treatment facility, such as a Level 2 medical unit. In typical embodiments the device allows for site-specific controlled elution of an antimicrobial agent, such as Tobramycin, including defined elution over a period of time, such as 48 or 72 hours. | 01-26-2012 |
20120148852 | SILANE COATING COMPOSITIONS, COATING SYSTEMS, AND METHODS - The present invention relates to coating systems and coating systems on substrates. In an embodiment, the invention includes an article including a substrate, a base layer disposed on the substrate, the base layer comprising a silane compound with a photoreactive group, or the reaction product of a silane compound with a photoreactive group, and a polymer layer disposed on the base layer, the polymer layer comprising a polymer terminally anchored to the base layer. In an embodiment, the invention includes a coating for an article. In an embodiment, the invention includes a method of depositing a coating onto a substrate. | 06-14-2012 |
20140142166 | COMPOSITION AND METHOD FOR DELIVERY OF HYDROPHOBIC ACTIVE AGENTS - Disclosed herein is a delivery composition for administering a hydrophobic active agent. In one embodiment, a delivery composition for local administration of a hydrophobic active agent to a tissue or organ of a patient is disclosed. In one embodiment, the delivery composition includes a cationic delivery agent, a therapeutically effective amount of a hydrophobic active agent and a pharmaceutically acceptable aqueous carrier. In one embodiment, the cationic delivery agent includes polyethyleneimine (PEI). In a more specific embodiment, the cationic delivery agent includes branched PEI. Methods of making the delivery composition, as well as kits and methods of use are also disclosed. | 05-22-2014 |
20140180229 | WOUND PACKING DEVICE AND METHODS - Embodiments of the invention include wound packing devices and methods of making and using the same. In an embodiment, the invention includes a wound packing device including a plurality of spacing elements capable of absorbing exudate, wherein the surface of the spacing elements resist colonization by microorganisms. The wound packing device can also include a connector connecting the plurality of spacing elements to one another. Other embodiments are also included herein. | 06-26-2014 |
20140200411 | CONDUCTIVE POLYMERS AND USES - Disclosed herein are activatable conductive compositions and methods of making and using activatable conductive compositions. In particular, activatable conductive monomers polymers are described and electrically conductive coatings that include activatable conductive polymers. | 07-17-2014 |
20140336571 | COMPOSITIONS AND METHODS FOR DELIVERY OF HYDROPHOBIC ACTIVE AGENTS - Disclosed herein is a delivery composition for administering a hydrophobic active agent. In one embodiment, a delivery composition for local administration of a hydrophobic active agent to a tissue or organ of a patient is disclosed. In one embodiment, the delivery composition includes a cationic delivery agent, a therapeutically effective amount of a hydrophobic active agent and a pharmaceutically acceptable aqueous carrier. In one embodiment, the cationic delivery agent includes polyethyleneimine (PEI). In an embodiment, the invention includes a drug delivery device including a substrate; and coated therapeutic agent particles disposed on the substrate, the coated therapeutic agent particles comprising a particulate hydrophobic therapeutic agent; and a vinyl amine polymer. Methods of making the delivery composition, as well as kits and methods of use are also included herein. | 11-13-2014 |